We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
France’s Innate Pharma has gained rights to AstraZeneca’s recently approved leukaemia drug Lumoxiti, in a deal that expands a collaboration that began more than three years ago.